Metrics to compare | CHOSA | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipCHOSAPeersSector | |
|---|---|---|---|---|
P/E Ratio | −7.8x | −2.5x | −0.5x | |
PEG Ratio | −0.35 | 0.05 | 0.00 | |
Price/Book | 2.9x | 3.4x | 2.6x | |
Price / LTM Sales | 11.8x | 5.0x | 3.2x | |
Upside (Analyst Target) | - | 145.5% | 50.8% | |
Fair Value Upside | Unlock | 34.3% | 7.7% | Unlock |
Chosa Oncology AB, together with its subsidiaries, engages in developing and commercializing medicines for the treatment of cancer in Sweden. It offers Platin-DRP, a multigene mRNA-based algorithm that predicts a patient’s response to platinum-based chemotherapy; and LiPlaCis, a liposomal formulation of cisplatin, enabling delivery of chemotherapy agent directly to tumor sites. The company has a collaboration with Icahn School of Medicine to test biomarker guiding platin-immunotherapy in lung cancer. The company was formerly known as Chosa ApS. Chosa Oncology AB was incorporated in 2015 and is based in Malmö, Sweden.